百心安-B(02185)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02185 百心安-B

已收盘 10-07 15:34:10

1.375

-0.040

-2.83%

最高1.415	最低1.360	成交量5.13万
今开1.415	昨收1.415	日振幅3.89%
总市值3.35亿	流通市值3.24亿	总股本2.43亿
成交额7.15万	换手率0.02%	流通股本2.36亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02185","market":"HK","secType":"STK","nameCN":"百心安-B","latestPrice":1.375,"timestamp":1791358450052,"preClose":1.415,"halted":0,"volume":51300,"delay":0,"changeRate":-0.02826855123674914,"floatShares":235703422,"shares":243417100,"eps":-0.3366449138255792,"marketStatus":"已收盘","change":-0.04,"latestTime":"10-07 15:34:10","open":1.415,"high":1.415,"low":1.36,"amount":71457,"amplitude":0.038869,"askPrice":1.4,"askSize":500,"bidPrice":1.375,"bidSize":8800,"shortable":0,"etf":0,"ttmEps":-0.36282060873045774,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791423000000},"marketStatusCode":5,"adr":0,"listingDate":1640188800000,"exchange":"SEHK","adjPreClose":1.415,"openAndCloseTimeList":[[1791336600000,1791345600000],[1791349200000,1791360000000]],"volumeRatio":1.189152,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02185/tweets","defaultTab":"tweets","newsList":[{"id":"1156734317","title":"百心安-B更新9月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1156734317","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156734317?lang=zh_cn&edition=full","pubTime":"2026-10-05 17:10","pubTimestamp":1791191454,"startTime":"0","endTime":"0","summary":"上海百心安生物技术股份有限公司（股票代码：02185，简称“百心安-B”）于2026年10月5日披露截至2026年9月30日的股份变动月报表。报告期内，公司法定/注册股本合计2.43亿元（对应总股数243,417,100股），无新增发行或库藏股份变动。\n根据月报，H股数量维持在235,703,422股，非上市外资股为7,713,678股，两类股份持股数均较上月底无变化。公司同时确认满足香港联交所对于公众持股量的相关规定，未发现任何购回、注销或其他股份变动情形。\n上述月报由执行董事兼联席公司秘书王云磬签署。公司表示将继续遵守香港联交所《上市规则》和相关监管要求，并按时进行公告披露。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135566837","title":"百心安-B：独立非执行董事陈轶青收警示函　公司评估对经营无重大不利影响","url":"https://stock-news.laohu8.com/highlight/detail?id=1135566837","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135566837?lang=zh_cn&edition=full","pubTime":"2026-09-16 21:45","pubTimestamp":1789566340,"startTime":"0","endTime":"0","summary":"百心安-B9月16日公告称，独立非执行董事陈轶青收到中国证券监督管理委员会天津监管局于2026年9月14日出具的《警示函》。警示函指向陈轶青在中源协和细胞基因工程股份有限公司任职期间对该公司2025年7月订立的一项关联方交易信息披露违规负有责任，并将该监管措施记入证券期货市场诚信档案。董事会评估认为，陈轶青收到警示函的事项不会对本集团的经营、财务状况或业务发展产生任何重大不利影响。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667560699","title":"百心安-B(02185)与申淇医疗订立战略合作协议 以推进BIOHEART®生物可吸收雷帕霉素洗脱冠状动脉支架系统的商业化","url":"https://stock-news.laohu8.com/highlight/detail?id=2667560699","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667560699?lang=zh_cn&edition=full","pubTime":"2026-09-15 06:26","pubTimestamp":1789424797,"startTime":"0","endTime":"0","summary":"根据战略合作协议，双方将充分发挥各自在市场渠道开发及学术推广方面的资源优势，共同推进BioHeart支架的商业化及临床应用。BioHeart支架为本公司自主开发的新一代生物可吸收雷帕霉素洗脱冠状动脉支架系统。董事会认为，本公司与申淇医疗订立战略合作协议代表本公司推进商业化进程及加快产品市场采用的重要一步。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495946.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1100","159891","02185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151069625","title":"百心安生物技术推进Bioheart生物可吸收雷帕霉素洗脱冠状动脉支架系统商业化合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1151069625","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1151069625?lang=zh_cn&edition=full","pubTime":"2026-09-15 06:22","pubTimestamp":1789424531,"startTime":"0","endTime":"0","summary":"百心安生物技术公司近日宣布达成一项关键合作，旨在加速其创新产品——Bioheart生物可吸收雷帕霉素洗脱冠状动脉支架系统的商业化进程。通过引入战略合作伙伴，百心安有望整合各方资源，强化市场推广渠道，并为这一备受瞩目的支架系统铺平上市之路。Bioheart系统作为新一代生物可吸收支架，不仅具备传统金属支架的支撑能力，还能够在完成血管修复使命后逐步降解，从而减少长期留存体内可能带来的风险。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1100","02185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195919235","title":"百心安生物科技与上海申淇医疗签署战略合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1195919235","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195919235?lang=zh_cn&edition=full","pubTime":"2026-09-15 06:22","pubTimestamp":1789424528,"startTime":"0","endTime":"0","summary":"百心安生物科技宣布，与上海申淇医疗科技有限公司正式达成战略合作框架协议。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02185","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106668810","title":"百心安-B(02185)：委任Giorgio Gobbi出任安通全球疗法开发副总裁","url":"https://stock-news.laohu8.com/highlight/detail?id=1106668810","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1106668810?lang=zh_cn&edition=full","pubTime":"2026-09-07 23:10","pubTimestamp":1788793844,"startTime":"0","endTime":"0","summary":"2026年9月7日，上海百心安生物技术股份有限公司发布自愿公告称，前美敦力及ReCor Medical高级管理人员Giorgio Gobbi已加入公司非全资附属公司上海安通医疗科技有限公司，担任全球疗法开发副总裁，全面负责Iberis肾神经阻断系统的全球疗法开发工作。百心安-B董事会表示，相信Gobbi先生的行业经验和专业知识将为公司及安通的未来发展带来重要贡献。公告由百心安-B董事长兼执行董事汪立于2026年9月7日签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665431788","title":"百心安-B(02185)委任GIORGIO GOBBI为安通全球疗法开发副总裁","url":"https://stock-news.laohu8.com/highlight/detail?id=2665431788","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665431788?lang=zh_cn&edition=full","pubTime":"2026-09-07 22:58","pubTimestamp":1788793099,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百心安-B(02185)发布公告，曾任美敦力及ReCor Medical高级管理人员Giorgio Gobbi先生(Gobbi先生)已加入公司非全资附属公司上海安通医疗科技有限公司(安通)，担任全球疗法开发副总裁，并将全面负责Iberis®肾神经阻断(RDN)系统的全球疗法开发工作。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493080.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1100","02185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156273406","title":"百心安-B（02185）将于10月9日召开2026年首次临时股东大会 审议独立董事委任","url":"https://stock-news.laohu8.com/highlight/detail?id=1156273406","media":"公告速递","labels":["conferences","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156273406?lang=zh_cn&edition=full","pubTime":"2026-09-04 16:43","pubTimestamp":1788511439,"startTime":"0","endTime":"0","summary":"百心安-B9月4日在港交所发布公告称，公司董事会已决定于2026年10月9日（星期五）在中国上海市浦东新区张江高科技产业东区瑞庆路590号4幢3层302室召开2026年第一次临时股东大会，拟审议有关委任费女士为公司独立非执行董事的议案。为厘定有权出席并投票的H股股东名册，公司将于2026年9月19日（星期六）至2026年10月9日（星期五）暂停办理H股股份过户登记。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142815551","title":"百心安-B更新8月股份变动月报表，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1142815551","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142815551?lang=zh_cn&edition=full","pubTime":"2026-09-03 17:28","pubTimestamp":1788427713,"startTime":"0","endTime":"0","summary":"上海百心安生物技术股份有限公司于2026年9月3日发布截至2026年8月31日的股份变动月报表。报告显示，公司在本月内未发生新增发行、购回、注销或库藏股活动，整体股本保持稳定。公告披露，截至8月末，百心安-B普通股H股已发行并上市的股份数为235,703,422股，非上市外资股数量为7,713,678股，两者均与上月底持平，注册股本总额为人民币243,417,100元。本次月报表由执行董事兼联席公司秘书王云磬签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662711207","title":"百心安-B(02185.HK)：费倩雯获提名为独立非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2662711207","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662711207?lang=zh_cn&edition=full","pubTime":"2026-08-26 20:46","pubTimestamp":1787748366,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02185","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662971149","title":"百心安-B(02185)发布中期业绩，除税前亏损3337.5万元 同比增加21.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662971149","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662971149?lang=zh_cn&edition=full","pubTime":"2026-08-26 20:43","pubTimestamp":1787748182,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百心安-B(02185)发布截至2026年6月30日止6个月中期业绩，该集团取得收益1437.7万元，同比减少31.09%;除税前亏损3337.5万元，同比增加21.72%;每股亏损0.13元。截至2026年6月30日止6个月，公司确认收入1440万元(截至2025年6月30日止6个月：2090万元)，包括销售货品1250万元及来自合作收益的190万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1486367.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1100","02185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139955284","title":"百心安-B(02185)定于2026年8月26日召开董事会审议中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1139955284","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1139955284?lang=zh_cn&edition=full","pubTime":"2026-08-14 16:37","pubTimestamp":1786696645,"startTime":"0","endTime":"0","summary":"百心安-B(02185)14日公告，公司董事会将于2026年8月26日（星期三）召开会议，审议并批准公司及其附属公司截至2026年6月30日止六个月的中期业绩及其发布事宜，并考虑派付中期股息（如有）。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187364121","title":"百心安-B更新7月股份变动月报表，股本保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1187364121","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187364121?lang=zh_cn&edition=full","pubTime":"2026-08-06 11:15","pubTimestamp":1785986129,"startTime":"0","endTime":"0","summary":"上海百心安生物技术股份有限公司于2026年8月6日公布截至2026年7月31日的证券变动月报表，报告期内公司股本结构未发生任何变动。根据报告显示，百心安-B于本月末普通股H股已发行股份总数保持在235,703,422股，无库存股份，非上市外资股维持在7,713,678股，法定注册股本合计仍为人民币243,417,100元。报告期内，公司不存在新增发行、股份购回或注销，以及库存股变化等情形，股份期权、权证、可换股票据等其他潜在股权安排亦无更新。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653084756","title":"Wang Philip Li增持百心安-B(02185)1万股 每股作价2.345港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2653084756","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653084756?lang=zh_cn&edition=full","pubTime":"2026-07-24 19:16","pubTimestamp":1784891770,"startTime":"0","endTime":"0","summary":"7月24日，Wang Philip Li增持百心安-B(02185)1万股，每股作价2.345港元，总金额为2.345万港元。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20260724/20260724191636_62429.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260724/20260724191636_62429.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1472095.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["EWH","02185","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198401104","title":"百心安-B 2026年6月股份变动月报：股本结构维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1198401104","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198401104?lang=zh_cn&edition=full","pubTime":"2026-07-06 12:21","pubTimestamp":1783311668,"startTime":"0","endTime":"0","summary":"上海百心安生物技术股份有限公司于2026年7月6日发布2026年6月股份变动月报。报告期为2026年6月1日至6月30日。公司披露的法定/注册股本包括H股及非上市外资股两类。截至6月末，H股数量保持235,703,422股，面值每股人民币1元；非上市外资股数量为7,713,678股，面值每股人民币1元。公司法定/注册股本总额继续维持人民币243,417,100元不变。另据公告信息，本次月报由公司执行董事兼联席公司秘书王云磬签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646363167","title":"百心安-B(02185)委任汪立为董事长","url":"https://stock-news.laohu8.com/highlight/detail?id=2646363167","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2646363167?lang=zh_cn&edition=full","pubTime":"2026-06-26 22:18","pubTimestamp":1782483485,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百心安-B(02185)公布，汪立先生、王云磬先生及王佩丽女士获重选为第三届董事会执行董事。陈轶青先生、鲁旭波先生及蒋一斐先生获重选为第三届董事会独立非执行董事。公司第叁届董事会的任期为三年，自股东周年大会日期起计，任期届满后可膺选连任。紧随股东周年大会后，汪立先生获董事会一致选举为第三届董事会董事长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1459857.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02185","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642959694","title":"百心安-B(02185)：IBERIS® RDN系统在以色列注册","url":"https://stock-news.laohu8.com/highlight/detail?id=2642959694","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2642959694?lang=zh_cn&edition=full","pubTime":"2026-06-09 22:33","pubTimestamp":1781015617,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百心安-B 发布公告，最近，公司附属公司上海安通医疗科技有限公司(安通)研发的Iberis多极肾动脉射频消融导管系统已完成在以色列的注册。截至本公告日期，Iberis RDN系统是全球唯一获准使用经桡动脉方法和经股动脉入路方法的肾神经阻断产品。公司的最终目标是为全球患者提供门诊RDN手术。安通已于2016年于欧洲取得Iberis RDN系统的CE标志。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452263.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1100","RDN","LU0154245673.USD","BK4229","LU0154245756.USD","02185","BK4195"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191766096","title":"百心安-B 5月股份维持不变，股本结构保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1191766096","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191766096?lang=zh_cn&edition=full","pubTime":"2026-06-04 14:46","pubTimestamp":1780555595,"startTime":"0","endTime":"0","summary":"上海百心安生物技术股份有限公司于2026年6月4日发布2026年5月股份变动月报表，报告期截至2026年5月31日。根据公告，百心安-B本月内普通股包括于香港联交所上市的H股和非上市外资股，合计法定注册股本243,417,100元人民币。本月末，H股股本为235,703,422股，非上市外资股为7,713,678股，较上月均无增减变化，公司已发行股份及库存股总数维持不变，未发生新的发行、购回、注销或库藏股活动。公司确认已持续符合香港联交所证券上市规则相关规定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636285633","title":"RAYS Capital Partners Limited增持百心安-B(02185)78.98万股 每股作价约3.82港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2636285633","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2636285633?lang=zh_cn&edition=full","pubTime":"2026-05-19 19:49","pubTimestamp":1779191381,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，5月14日，RAYS Capital Partners Limited增持百心安-B(02185)78.98万股，每股作价3.8248港元，总金额约为302.08万港元。增持后最新持股数目为1482.68万股，最新持股比例为6.29%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443591.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02185","EWH","BK1100","RAYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636885635","title":"Asian Equity Special Opportunities Portfolio Master Fund Limited增持百心安-B(02185)69.98万股 每股作价3.82港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2636885635","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2636885635?lang=zh_cn&edition=full","pubTime":"2026-05-19 19:49","pubTimestamp":1779191344,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，5月14日，Asian Equity Special Opportunities Portfolio Master Fund Limited增持百心安-B(02185)69.98万股，每股作价3.82港元，总金额约为267.32万港元。增持后最新持股数目为1187.68万股，最新持股比例为5.03%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443588.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1100","02185","EWH"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bio-heart.com","stockEarnings":[{"period":"1week","weight":-0.0241},{"period":"1month","weight":-0.2204},{"period":"3month","weight":-0.5633},{"period":"6month","weight":-0.674},{"period":"1year","weight":-0.8204},{"period":"ytd","weight":-0.7556}],"compareEarnings":[{"period":"1week","weight":-0.0099},{"period":"1month","weight":-0.0534},{"period":"3month","weight":0.0034},{"period":"6month","weight":-0.0572},{"period":"1year","weight":-0.0993},{"period":"ytd","weight":-0.0527}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海百心安生物技术股份有限公司是一家主要从事介入医疗业务的中国公司。该公司的主营业务是介入式心血管装置的研发和生产。该公司的主要产品包括全降解支架（BRS）以及肾神经阻断（RDN）。该公司的产品主要用于满足治疗冠状、外周动脉疾病及高血压等的医疗需求。该公司的产品主要用于解决中国患者在治疗冠状动脉疾病方面的未满足医疗需求，以及解决患者在治疗未控高血压方面的未满足医疗需求。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.011646},{"month":2,"riseRate":0.2,"avgChangeRate":0.02525},{"month":3,"riseRate":0.4,"avgChangeRate":-0.005552},{"month":4,"riseRate":0.6,"avgChangeRate":0.105685},{"month":5,"riseRate":0.4,"avgChangeRate":-0.078912},{"month":6,"riseRate":0.6,"avgChangeRate":0.053931},{"month":7,"riseRate":0.4,"avgChangeRate":-0.005861},{"month":8,"riseRate":0.2,"avgChangeRate":0.086967},{"month":9,"riseRate":0.2,"avgChangeRate":-0.082471},{"month":10,"riseRate":0.4,"avgChangeRate":0.033583},{"month":11,"riseRate":0.25,"avgChangeRate":-0.154388},{"month":12,"riseRate":0.25,"avgChangeRate":-0.236848}],"exchange":"SEHK","name":"百心安-B","nameEN":"BIOHEART-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百心安-B(02185)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百心安-B(02185)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百心安-B,02185,百心安-B股票,百心安-B股票老虎,百心安-B股票老虎国际,百心安-B行情,百心安-B股票行情,百心安-B股价,百心安-B股市,百心安-B股票价格,百心安-B股票交易,百心安-B股票购买,百心安-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百心安-B(02185)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百心安-B(02185)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}